- Organizations: Horizon Therapeutics
Business
FTC approves final consent order following lawsuit against Amgen’s Horizon acquisition
Commission approves final order consent with major contingencies for Amgen following its October 2023-closed deal.
Business
Amgen's acquisition of Horizon is officially back on
FTC and companies agree to resolve antitrust lawsuit filed in May 2023.
Products
FDA adds new warning to Tepezza label
The TED therapy’s prescription label now cautions potential hearing impairment and loss.
Products
Horizon releases additional Tepezza phase 4 data for TED
New findings supports extended use, regardless of disease activity or duration.
Research
Horizon reports published data from phase 3 study on Uplizna
Results offer insight into Uplinza’s role in reducing biomarker levels associated with NMOSD.Legal
Amgen purchase of Horizon delayed after FTC lawsuit
Company agrees to push back the transaction date until September 2023 or later; action is a first for the agency.Products
FDA expands Tepezza indication for TED patients
Updated indications and usage includes specifications for treatment.
Pipeline
Positive data reported for phase 4 study on Tepezza for TED
Horizon Therapeutics’s trial is evaluating teprotumumab-trbw in patients with CAS thyroid eye disease.
Research
Real-world data supports Tepezza for dysthyroid optic neuropathy
Analysis on patients treated with the FDA-approved drug shows promising results.
Pipeline
Horizon releases phase 2 trial results of dazodalibep for Sjögren’s syndrome
The second of two population studies met its primary endpoint.
Business